All In Biotech

NDA 020397 · Legacy

Zanaflex

Tizanidine Hydrochloride · Oral

NovelOrphan

Last checked: Nov 19, 2026Latest source record: Nov 22, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Nov 27, 1996

Approved uses

1

Original approval plus efficacy supplements

Registered trials

46

9 Phase 3, 5 recruiting

FAERS reports

18,291

10,734 serious, 898 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 2, 2026.

Zanaflex is indicated for the treatment of spasticity in adults. Zanaflex is a central alpha-2-adrenergic agonist indicated for the treatment of spasticity. ( 1 )

Mechanism: Tizanidine is a central alpha-2-adrenergic receptor agonist and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons. 12.2 Pharmacodynamics The CNS depressant effects of tizanidine and alcohol are additive [see Warnings and Precautions ( 5.3 ) and Drug Interactions ( 7.4 )]

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 27, 1996 Original approval · Type 1 - New Molecular Entity Review
2 products under this application
  • ZANAFLEX · TIZANIDINE HYDROCHLORIDE EQ 2MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
  • ZANAFLEX · TIZANIDINE HYDROCHLORIDE EQ 4MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Tizanidine" as an intervention, any sponsor and status, largest first.

All 46 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue1,549
  • nausea1,482
  • pain1,479
  • headache1,431
  • drug ineffective1,265
  • fall1,047
  • dizziness950
  • dyspnoea899
  • diarrhoea896
  • arthralgia824
  • vomiting788
  • depression777

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004314
2005356
2006337
2007237
2008314
2009364
2010494
2011521
2012700
2013584
2014727
20151,094
20161,403
20171,034
20181,054
20191,013
2020992
2021867
20221,234
20231,187
20241,249
20251,269
2026946

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zanaflex (Tizanidine HCl)

2024 spending

$455K

Beneficiaries

216

865 claims

Per beneficiary

$2,104

$3.96 per unit

View as table
YearSpending
2020$485,904
2021$555,937
2022$541,393
2023$503,081
2024$454,553

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 138 on PubMed

Sponsor: Legacy

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.